Ipecacuanha: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Rabin Bista (talk | contribs)
nocaptcha, Administrators
4,526 edits
No edit summary
Rabin Bista (talk | contribs)
nocaptcha, Administrators
4,526 edits
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
|authorTag=<!--Overview-->{{RB}}
|OTC=
|OTC=Yes
|genericName=Ipecacuanha
|aOrAn=a
|aOrAn=a
|indicationType=
|drugClass=OTC emetic
|indication=
|indicationType=treatment
|hasBlackBoxWarning=Yes
|indication= of Poisoning, acute by inducing vomiting
|adverseReactions=<!--Black Box Warning-->
|adverseReactions=Diarrhea, Stomach cramps, Myalgia and Lethargy
 
 
<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
 


<!--Adult Indications and Dosage-->
<!--Adult Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=====Indications====
 
* Poisoning, acute<ref name="pmid2865374">{{cite journal| author=Krenzelok EP, Dean BS| title=Syrup of ipecac in children less than one year of age. | journal=J Toxicol Clin Toxicol | year= 1985 | volume= 23 | issue= 2-3 | pages= 171-6 | pmid=2865374 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2865374  }} </ref><ref name="pmid2900493">{{cite journal| author=Litovitz T| title=In defense of retaining ipecac syrup as an over-the-counter drug. | journal=Pediatrics | year= 1988 | volume= 82 | issue= 3 Pt 2 | pages= 514-6 | pmid=2900493 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2900493  }} </ref>
* Dosing Information
* to induce NAUSEA AND VOMITING
 
:* Dosage
 
=====Condition2=====


* Dosing Information
====Dosage====
 
(Adults / Children 2-18 years): Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional.
:* Dosage
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=====Indications====
 
* Poisoning, acute<ref name="pmid2865374">{{cite journal| author=Krenzelok EP, Dean BS| title=Syrup of ipecac in children less than one year of age. | journal=J Toxicol Clin Toxicol | year= 1985 | volume= 23 | issue= 2-3 | pages= 171-6 | pmid=2865374 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2865374  }} </ref>
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:  
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====


There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
====Dosage====
(Adults / Children 2-18 years): Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
|contraindications=


<!--Warnings-->
<!--Warnings-->
|warnings=* Description
|warnings=* Enter section text here
 
====Precautions====


* Description
Do not use if pellet-dispenser seal is broken.
Stop use and ask a doctor if symptoms persist more than 3 days or worsen.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children.


<!--Adverse Reactions-->
<!--Adverse Reactions-->


<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=* Diarrhea<ref name="pmid2860632">{{cite journal| author=Czajka PA, Russell SL| title=Nonemetic effects of ipecac syrup. | journal=Pediatrics | year= 1985 | volume= 75 | issue= 6 | pages= 1101-4 | pmid=2860632 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2860632  }} </ref>
 
* Stomach cramps
=====Body as a Whole=====
* Myalgia
 
* Lethargy<ref name="pmid2860632">{{cite journal| author=Czajka PA, Russell SL| title=Nonemetic effects of ipecac syrup. | journal=Pediatrics | year= 1985 | volume= 75 | issue= 6 | pages= 1101-4 | pmid=2860632 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2860632  }} </ref>
 
|drugInteractions=
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description


<!--Use in Specific Populations-->
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* If pregnant or breast-feeding, ask a health professional before use
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInNursing=* If pregnant or breast-feeding, ask a health professional before use
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
Line 269: Line 82:
|administration=* Oral
|administration=* Oral


* Intravenous
 
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description
 


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 278: Line 91:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Overdose</i> of {{PAGENAME}} in the drug label.
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


<!--Pharmacology-->
<!--Pharmacology-->
Line 299: Line 100:


<!--Structure-->
<!--Structure-->
|structure=*  
|structure=* ACTIVE INGREDIENT HPUS
IPECACUANHA 3X
 
(Ipecac)
 
INACTIVE INGREDIENTS
Lactose, sucrose.
 


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
Line 317: Line 124:
<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|storage=* Store at room temperature.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|packLabel=====LABEL====
: [[File:Ipecacuanha PDP.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
====Ingredients and Appearance====
: [[File:Ipecacuanha Ing and App.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Precautions with Alcohol-->
<!--Patient Counseling Information-->
|fdaPatientInfo=QUESTIONS?
1-800-404-4666
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
|brandNames=* IPECACUANHA®<ref>{{Cite web | title = Ipecacuanha pellet | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dde3c03-7b16-4de5-aec1-e9fda7e2fba0}}</ref>


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->

Revision as of 20:52, 16 February 2015

Ipecacuanha
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Ipecacuanha is a OTC emetic that is FDA approved for the treatment of of Poisoning, acute by inducing vomiting. Common adverse reactions include Diarrhea, Stomach cramps, Myalgia and Lethargy.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • Poisoning, acute[1][2]
  • to induce NAUSEA AND VOMITING

Dosage

(Adults / Children 2-18 years): Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ipecacuanha in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ipecacuanha in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indications

  • Poisoning, acute[1]

Dosage

(Adults / Children 2-18 years): Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ipecacuanha in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ipecacuanha in pediatric patients.

Contraindications

There is limited information regarding Ipecacuanha Contraindications in the drug label.

Warnings

  • Enter section text here

Do not use if pellet-dispenser seal is broken. Stop use and ask a doctor if symptoms persist more than 3 days or worsen. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.

Adverse Reactions

Clinical Trials Experience

  • Diarrhea[3]
  • Stomach cramps
  • Myalgia
  • Lethargy[3]

Postmarketing Experience

There is limited information regarding Ipecacuanha Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Ipecacuanha Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • If pregnant or breast-feeding, ask a health professional before use


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ipecacuanha in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ipecacuanha during labor and delivery.

Nursing Mothers

  • If pregnant or breast-feeding, ask a health professional before use

Pediatric Use

There is no FDA guidance on the use of Ipecacuanha with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Ipecacuanha with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Ipecacuanha with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ipecacuanha with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ipecacuanha in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ipecacuanha in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ipecacuanha in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ipecacuanha in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Ipecacuanha in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Ipecacuanha in the drug label.

Overdosage

There is limited information regarding Overdose of Ipecacuanha in the drug label.

Pharmacology

There is limited information regarding Ipecacuanha Pharmacology in the drug label.

Mechanism of Action

Structure

  • ACTIVE INGREDIENT HPUS

IPECACUANHA 3X

(Ipecac)

INACTIVE INGREDIENTS Lactose, sucrose.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Ipecacuanha in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Ipecacuanha in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Ipecacuanha in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Ipecacuanha in the drug label.

How Supplied

Storage

  • Store at room temperature.

Images

Drug Images

{{#ask: Page Name::Ipecacuanha |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

LABEL

This image is provided by the National Library of Medicine.

Ingredients and Appearance

This image is provided by the National Library of Medicine.

{{#ask: Label Page::Ipecacuanha |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

QUESTIONS? 1-800-404-4666

Precautions with Alcohol

  • Alcohol-Ipecacuanha interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • IPECACUANHA®[4]

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ 1.0 1.1 Krenzelok EP, Dean BS (1985). "Syrup of ipecac in children less than one year of age". J Toxicol Clin Toxicol. 23 (2–3): 171–6. PMID 2865374.
  2. ↑ Litovitz T (1988). "In defense of retaining ipecac syrup as an over-the-counter drug". Pediatrics. 82 (3 Pt 2): 514–6. PMID 2900493.
  3. ↑ 3.0 3.1 Czajka PA, Russell SL (1985). "Nonemetic effects of ipecac syrup". Pediatrics. 75 (6): 1101–4. PMID 2860632.
  4. ↑ "Ipecacuanha pellet".
  5. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Ipecacuanha
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Ipecacuanha
 |Label Name=Ipecacuanha11.png

}}

{{#subobject: 

 |Label Page=Ipecacuanha
 |Label Name=Ipecacuanha11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Ipecacuanha&oldid=1069413"